Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and related weight-loss medications have transformed what is achievable through medical weight management.1,2 As larger and faster weight reductions become more common through the growing use of these medications, dermatologists are increasingly encountering the cutaneous trade-offs of that success
The magnitude of this weight loss itself isn’t unfamiliar. What has changed is the timing and convergence of its dermatologic effects. Facial deflation, skin laxity, and telogen effluvium are now appearing earlier in the course of weight loss, often overlapping in the same patients rather than unfolding gradually over time. An age-old adverse effect of injectable medications, injection-site complications, is becoming more common as the population of GLP-1 RA users expands
“These medications produce weight loss we’ve never seen before outside bariatric surgery,” says Joshua Zeichner, MD, director of Cosmetic and Clinical Research in the department of dermatology at Mount Sinai. “The skin can’t always keep up.“
When weight comes off quickly, the skin simply doesn’t have time to recoil
Skin Laxity: Accelerated Presentation, Higher Stakes
Skin laxity has emerged as one of the most common cutaneous adverse effects experienced among GLP-1 receptor agonist users.3
“When weight comes off quickly, the skin simply doesn’t have time to recoil,” says Mary Alice Mina, MD, a Mohs-micrographic surgeon and assistant professor at Emory University School of Medicine. “It behaves like a balloon. Once you let the air out, the surface collapses.”
Bariatric surgery populations offer the closest comparison for understanding how skin responds to rapid, high-volume weight loss. Studies have shown that patients who underwent bariatric surgery typically lost 50% or more of their initial BMI, resulting in pronounced laxity often requiring aesthetic surgical intervention for resolution. Though weight loss tends to occur at a smaller proportion of total BMI than patients who underwent bariatric surgery, similar outcomes are now being seen among GLP-1 RA users who experience rapid, large-scale weight loss.4
The rate of weight loss is key. Rapid weight loss, widely regarded as reductions exceeding 1 to 2 pounds per week, is associated with poorer dermal recoil and greater skin redundancy.3-5
“I’m seeing thigh, abdomen, and arm skin that looks like post-massive weight loss,” Dr Mina says. “The skin can’t snap back when the weight comes off too fast.”
Not all patients are affected equally. Dr Zeichner notes that those who enter weight loss with worse baseline skin quality, such as lower baseline collagen reserves, tend to experience more pronounced and persistent skin changes
“Age, hormonal changes, and how long the skin has been stretched all influence how well the skin will recoil,” he says
Collagen and elastic fiber production begin to decline in early adulthood, with more substantial losses seen in the fourth and fifth decades.6 Declining estrogen levels in peri- and postmenopausal women further reduce elasticity.7 Skin that has been stretched for many years, such as in long-standing obesity, has a diminished capacity to contract once weight is lost, he notes
When rapid, high-volume weight loss occurs against that backdrop, the result can be extensive redundant skin. “Those are the patients who really struggle,” Dr Zeichner adds. “Their skin simply doesn’t have the elasticity to recover on its own.”
Facial Volume Loss: When Deflation Happens Fast
Facial volume loss, often referred to as Ozempic® face, has become a common concern among GLP-1 RA users, particularly because it is often visible within weeks or months of initiating these medications.8
“This happens with weight loss in general,” says Dr Mina. “The face is often the first place people lose fat. But when the weight comes off fast, the change can look dramatic.”
Rapid deflation of facial fat pads can accentuate jowling and neck laxity, leaving patients appearing gaunt even when they are pleased with their overall weight loss.3 The compressed timeline appears to amplify the visual impact, especially in those whose facial contours change before other areas of the body, she says
Dr Mina notes that the reaction is often driven as much by perception as by anatomy.“We’re used to seeing someone look a certain way,” she says. “When that changes quickly, it can be jarring.”
Hair Shedding: A Delayed but Distressing Effect
Hair shedding is another common concern, but often a delayed one
“This is classic telogen effluvium,” says Dr Mina. “It happens after a stress on the body, and rapid weight loss absolutely qualifies.”
Patients come in after noticing clumps of hair in the shower or brush, prompting fears of permanent hair loss, she notes. Because there’s often a delay of several months between weight loss and hair loss, people don’t always connect it to weight loss
“That can make it especially alarming,” she says
While telogen effluvium can be dramatic, both dermatologists emphasize that it is non-scarring and usually reversible. And recovery takes time
“Shedding can take a year to correct itself,” Dr Zeichner says. “Because hair grows slowly, it may take much longer for hair to return to baseline.”
But dermatologists should not assume all hair shedding is solely related to weight loss with GLP-1 RAs. Nutritional deficiencies (particularly protein, iron, and zinc) can worsen hair shedding.9 Other forms of alopecia should be ruled out
Injection-Site Reactions
Injection-site complications have been reported in up to 20% of patients using GLP-1 RAs.9
“Some present as deep, painful nodules that turn out to be infections rather than simple inflammation,” Dr Mina says.
Because injections are delivered into subcutaneous fat, suspected infections may be slow to resolve and can result in scarring. Atypical organisms — including mycobacteria and fungi — may be involved, making early biopsy and culture important rather than empiric treatment alone, Dr Mina notes. In her experience, complications appear more frequently in patients injecting compounded products or receiving injections outside standard pharmacy pathways
“The key is not assuming what you’re dealing with,” Dr Mina says. ‘If there’s a persistent, painful nodule, you need to work it up.”
Why Pacing Matters
Across skin laxity, facial deflation, and hair shedding, there’s a common driver: the speed of the weight loss often matters as much as the amount of weight lost
“From a skin standpoint, slow and steady is always better,” says Dr Zeichner
As bariatric experience has shown, faster weight loss leaves the skin with less opportunity to adapt, increasing the likelihood of persistent laxity and the desire for surgical correction.10,11
Dr Mina says this aligns closely with what she is now seeing in patients on GLP-1 RAs
“The people I don’t see struggling as much are those losing weight more slowly,” she says. “When the body isn’t shocked, the skin and hair seem to handle the change better.”
Hair shedding follows a similar trajectory. Telogen effluvium is a well-recognized response to rapid weight loss and is less commonly seen when weight loss is more gradual, she adds
How Dermatologists Are Managing These Changes
For dermatologists, managing skin changes associated with GLP-1 RAs isn’t about reinventing practice. It’s about recognizing these patterns earlier, understanding who is most likely to experience adverse effects, and helping patients navigate what their skin can and cannot do during rapid weight loss
Both clinicians emphasize that intervening while weight loss is still underway can make a meaningful difference, particularly for skin quality and early laxity
“We see better responses when we’re supporting collagen while the weight is coming off, not after everything has already deflated,” says Dr Zeichner.
In practice, that often means paying closer attention to baseline skin health. Measures that protect collagen such as photoprotection and topical retinoids may matter more during periods of rapid weight change, he adds
Loss of muscle mass is another factor that shouldn’t be overlooked, says Dr Mina.
“With this dramatic weight loss, it’s not always just fat, it’s also muscle,” she says. “People really need to be eating enough protein and doing resistance training, because when muscle goes, the skin laxity is much more noticeable.”
Facial volume loss should be approached with similar caution. Early changes may respond to conservative volumization or collagen-stimulating strategies, but rapid, high-volume weight loss can produce deflation that is difficult to reverse fully, Dr Mina says
“The face changes first, and patients notice it immediately,” she adds. “But if the weight loss is ongoing, you have to be careful not to overcorrect too early.”
Hair shedding, while distressing, is generally managed through reassurance and evaluation rather than aggressive intervention. Both dermatologists emphasize ruling out differential diagnoses, while counseling patients on the expected timeline for recovery
When it comes to procedural interventions, both dermatologists stress realistic expectations. Nonsurgical treatments may improve skin texture, quality, and mild to moderate laxity, but they are less effective once extensive redundancy has developed
“There’s a point where the amount of excess skin is simply beyond what dermatology can fix,” Dr Mina says. “That’s when surgical removal becomes the only meaningful option.”
This article originally appeared on Dermatology Advisor
- Wilding JPH, Batterham RL, Calanna S, et al; for the STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity.N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
- Jastreboff AM, Aronne LJ, Ahmad NN, et al; for the SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med.2022;387(3):205–216. doi:10.1056/NEJMoa2206038
- Haykal D, Hersant B, Cartier H, Meningaud J-P. The role of GLP-1 agonists in esthetic medicine: exploring the impact of semaglutide on body contouring and skin health. J Cosmet Dermatol. 2025;24(2):e16716. doi:10.1111/jocd.16716
- Nikolis A, Enright KM, Fabi SG, et al. Consensus statements on managing aesthetic needs in prescription medication-driven weight loss patients: an international, multidisciplinary Delphi study. J Cosmet Dermatol. 2025;24(4):e70094. doi:10.1111/jocd.70094
- The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. National Heart, Lung, and Blood Institute. Published October 2000. Accessed May 19, 2026. https://www.nhlbi.nih.gov/files/docs/guidelines/prctgd_c.pdf
- Swift A, Liew S, Weinkle S, Garcia JK, Silberberg MB. The facial aging process from the “inside out.”Aesthet Surg J. 2020;41(10):1107-1119. doi:10.1093/asj/sjaa339
- Hussein RS, Dayel SB, Abahussein O, El-Sherbiny AA. Influences on skin and intrinsic aging: biological, environmental, and therapeutic insights.J Cosmet Dermatol. 2025;24(2):e16688. doi:10.1111/jocd.16688
- Humphrey CD, Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39(6):719-721. doi:10.1055/a-2148-6321
- Burke OM, Sa B, Alvarez Cespedes D, Tosti A. Dermatologic implications of glucagon-like peptide-1 receptor agonist medications. Skin Appendage Disord. 2025;11(5):416-423. doi:10.1159/000544023
- Kitzinger HB, Abayev S, Pittermann A, et al. After massive weight loss: patients’ expectations of body contouring surgery.Obes Surg. 2012;22:544-548. doi:10.1007/s11695-011-0551-6
- Gusenoff JA, Messing S, O’Malley W, Langstein HN. Temporal and demographic factors influencing the desire for plastic surgery after gastric bypass surgery.Plast Reconstr Surg. 2008;121(6):2120-2126. doi:10.1097/PRS.0b013e31817081a3
